Please assess the completion status of the following clinical trial:

Trial Title: PEG-Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed renal cell carcinoma~  * Metastatic disease~ * No prior therapy for advanced disease~* Tumor sample available for molecular analysis with prior registration on MSKCC IRB # 89-076~* Bidimensionally measurable disease~* No brain metastases unless completely resected and without evidence of recurrence for at least six months~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* Karnofsky 70-100%~Life expectancy~* Not specified~Hematopoietic~* WBC at least 3,000/mm3~* Platelet count at least 100,000/mm3~Hepatic~* Bilirubin no greater than 1.5 mg/dL~* SGOT no greater than 2.5 times upper limit of normal (unless due to hepatic metastases)~* Hepatitis B surface antigen negative~* Hepatitis C negative~Renal~* Creatinine no greater than 2 mg/dL~Cardiovascular~* No severe cardiac disease~* No New York Heart Association class III or IV cardiac disease~* No myocardial infarction within the past 12 months~* No ventricular tachyarrhythmias requiring ongoing treatment~* No unstable angina~Pulmonary~* No severe asthma requiring chronic systemic steroids~Other~* HIV negative~* Negative pregnancy test~* Fertile patients must use effective contraception~* No malignancy within the past 2 years except basal cell or squamous cell skin cancer, superficial bladder cancer, or localized prostate cancer~  * Patients who have undergone potentially curative therapy and have been deemed to be at low risk for recurrence are eligible~* No medically significant psychiatric disease (e.g., endogenous depression, psychosis, or bipolar disease) requiring hospitalization~* No prior or active autoimmune disease~* Medically controlled diabetes or thyroid dysfunction allowed~* No clinically significant acute viral or bacterial infection that requires specific therapy~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No prior interleukin-2~* No prior interferon alfa~* No concurrent cytokines or biological response modifiers except epoetin alfa in the case of hematologic compromise~* No concurrent tumor vaccines~* No concurrent monoclonal antibodies~* No concurrent bone marrow/stem cell transplantation~Chemotherapy~* No concurrent cytotoxic agents~Endocrine therapy~* No concurrent high-dose systemic steroids~* Concurrent low-dose corticosteroids (e.g., asthma inhalers, topical creams, or intra-articular injections) allowed~* No concurrent hormonal therapy (including megestrol)~* Concurrent hormone replacement therapy or oral contraceptives allowed~Radiotherapy~* At least 4 weeks since prior radiotherapy~* No concurrent radiotherapy~Surgery~* See Disease Characteristics~* At least 4 weeks since prior major surgery~* Concurrent nephrectomy allowed~Other~* At least 14 days since prior anti-infectious therapy~* No other concurrent investigational drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete